Trial Profile
A case control study defining genetic and nongenetic determinants for treatment-limiting renal tubular injury in HIV infected individuals exposed to tenofovir disoproxil fumarate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacogenomic
- 11 Feb 2016 Accural to date is 124% as reported by United Kingdom Clinical Research Network.
- 11 Feb 2016 Planned End Date changed from 3 Aug 2014 to 30 Nov 2015 as reported by United Kingdom Clinical Research Network.
- 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.